STRO-001

STRO-001 is a site-specific, fully human, aglycosylated anti-CD74 antibody-drug conjugate (ADC) developed using a novel cell-free protein synthesis and site-specific conjugation platform. It incorporates two non-cleavable maytansinoid linker-warheads per antibody molecule (drug-antibody ratio of 2). The drug targets CD74, which is highly expressed on malignant B cells in diseases such as multiple myeloma and non-Hodgkin lymphoma. Upon binding to CD74-expressing tumor cells, the ADC is internalized and releases its cytotoxic payload, leading to targeted cell death while minimizing off-target toxicity. Preclinical studies have demonstrated potent antitumor activity in multiple myeloma models as well as efficacy against acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-ALL) models. STRO-001 has received Orphan Drug designation for multiple myeloma and is currently being evaluated in Phase 1 clinical trials for relapsed/refractory multiple myeloma and B-cell malignancies[1][2][3][4][5][6].

Other names

bezetabart debotansine